Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Mar 2025 value amounting to $161.0 million.

  • Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) rose 2.08% to $161.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $161.0 million, marking a year-over-year increase of 2.08%. This contributed to the annual value of $160.7 million for FY2020, which is 2.97% up from last year.
  • Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $161.0 million in Q1 2025, which was up 1.23% from $159.0 million recorded in Q2 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $161.0 million during Q1 2025, and registered a low of $155.4 million during Q2 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $158.3 million, with a median of $158.4 million in 2024.
  • Data for Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY rose of 2.35% (in 2024) over the last 5 years.
  • Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $155.4 million in 2023, then grew by 2.35% to $159.0 million in 2024, then increased by 2.08% to $161.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $161.0 million in Q1 2025, compared to $159.0 million in Q2 2024 and $157.7 million in Q1 2024.